Vogenx IPO
Vogenx, Inc. · Clinical-stage biopharmaceuticals
- Issue price
- $13per share
- Issue size
- $81.25M62,50,000 shares
- Face value
- To be announcedper equity share
- Lot size
- To be announcedMin. investment shown once set
- PricingTue, 2026
Information only, not investment advice. This page provides information compiled from official SEC filings for information purposes only. It is not investment advice or a recommendation to buy or sell any security. IPO investments involve risk, including loss of principal; read the prospectus carefully before investing.
Issue details
- Issue type
- Firm commitment, fresh issue
- Fresh issue
- 62,50,000 shares ($75.56M)
- Offer for sale
- None
- Total issue
- 62,50,000 shares ($81.25M)
- Face value
- —
- Listing at
- Nasdaq
Source: Final prospectus (Form 424B4) dated 12 Aug 2026Updated
Valuation
Year ended December 31, 2024- EPS (basic)
- -$0.4
- EPS (diluted)
- -$0.4
- EPS (basic) (Year ended December 31, 2025)
- -$0.27
- EPS (diluted) (Year ended December 31, 2025)
- -$0.27
- EPS (basic) (Three months ended March 31, 2025)
- -$0.07
- EPS (diluted) (Three months ended March 31, 2025)
- -$0.07
- EPS (basic) (Three months ended March 31, 2026)
- -$0.09
- EPS (diluted) (Three months ended March 31, 2026)
- -$0.09
Source: Final prospectus (Form 424B4) dated 12 Aug 2026Updated
Financials
Standalone, restated · ₹ crore| Period ended | 31 Mar 20263 months | 31 Dec 202512 months | 31 Mar 20253 months | 31 Dec 202412 months |
|---|---|---|---|---|
| Profit after tax | -0.05 | -0.14 | -0.04 | -0.22 |
| Net worth | -0.14 | — | — | — |
| Total assets | 0.09 | — | — | — |
12 months vs 12 months: profit after tax +34.4%. Periods shorter than 12 months are shown as reported and are not annualised.
Source: Final prospectus (Form 424B4) dated 12 Aug 2026Updated
About the company
Vogenx is a clinical-stage biopharmaceutical company founded in 2021 that focuses on treating serious metabolic diseases. Its lead candidate, mizagliflozin, is a minimally absorbed SGLT1 inhibitor being developed for post-bariatric hypoglycemia, gastroparesis and GIP-dependent Cushing's Syndrome. The company has no approved products and has not generated product revenue.
- Incorporated
- —
- Industry
- Clinical-stage biopharmaceuticals
- Sector
- Healthcare and Pharma
- Website
- vogenx.com
Source: Final prospectus (Form 424B4) dated 12 Aug 2026Updated
Promoters and shareholders
| Name | Before issue | After issue |
|---|---|---|
| James Green | 26.50% | 13.70% |
| William Wilkison | 26.50% | 13.70% |
| Steven Delmar | 10.90% | 5.70% |
| Richard Cheatham | 10.50% | 5.40% |
| Lypul, Ltd. | 9.00% | 4.30% |
| Maxim Partners LLC | 6.20% | 3.20% |
Source: Final prospectus (Form 424B4) dated 12 Aug 2026Updated
Objects of the issue
₹ crore| Purpose | Amount |
|---|---|
| Advance mizagliflozin for post-bariatric hypoglycemia through the Phase 2b EMERGE study | 2.63 |
| Advance mizagliflozin for gastroparesis through a Phase 2 proof of concept trial | 2.04 |
| Pay certain accrued expenses, including accrued employee salary and bonus | 0.08 |
| Discovery research, additional clinical development, general corporate purposes and working capital, with any remainder | Set with price |
Source: Final prospectus (Form 424B4) dated 12 Aug 2026Updated
Strengths and risks
Our summary of what the offer document statesSource: Final prospectus (Form 424B4) dated 12 Aug 2026Updated
Contacts
Source: Final prospectus (Form 424B4) dated 12 Aug 2026Updated
After listing
Listing price, day-one high and low, and the change from the issue price ($13) appear here after the shares list on Nasdaq.
Work out the gain or loss on allotted shares after charges →
Frequently asked questions
What is the Vogenx IPO price band?
The final issue price is $13 per share.
Where will Vogenx shares list?
On Nasdaq.
How will the money raised be used?
$26.3M for , $20.4M for , $8,44,000 for , and the rest for the other stated purposes.
Related IPOs
Spotted something wrong?
Our data comes from official offer documents, but mistakes can slip through. Report an error and tell us which figure looks wrong and where you saw the correct one (the offer-document page number helps). For anything else, see Contact.